RET Research News and Information

Check out these blog posts from our Scientific Advisory Board members and other partners from the scientific community explaining the latest RET research.

2026 ret lung cancer research webinar
2026 RET Webinar: Meet Our Speakers

2026 RET Webinar: Meet Our Speakers

The 2026 RET Research Update is just around the corner, and we are excited to…
September 30, 2026
WCLC 2026 ret lung cancer research
New RET Research Advances from IASLC WCLC 2026

New RET Research Advances from IASLC WCLC 2026

IASLC World Conference on Lung Cancer (WCLC) 2026 featured important new research advancing the understanding…
September 16, 2026
genomic testing for lung cancer
RET-Fusion Positive NSCLC: Why Genomic Testing Matters for Your Treatment

RET-Fusion Positive NSCLC: Why Genomic Testing Matters for Your Treatment

Advances in biomarker science are reshaping how patients are diagnosed with and manage early-stage lung…
August 18, 2026
RET inhibitor and chemotherapy treatment for lung cancer
Continuing a RET Inhibitor With Chemotherapy After Progression May Improve Outcomes For RET Lung Cancer Patients

Continuing a RET Inhibitor With Chemotherapy After Progression May Improve Outcomes For RET Lung Cancer Patients

RET Inhibitor with chemotherapy after progression may improve outcomes for RET lung cancer patients
July 10, 2026
Dr Reuben RET lung cancer research on FOXM1
New FOXM1 T cell therapies that can target RET tumors

New FOXM1 T cell therapies that can target RET tumors

Researchers at MD Anderson Cancer Center have found that RET lung cancers have unusually high…
June 24, 2026
new NCCN RET lung cancer guidleines
What the New NCCN Guidelines Mean for RET+ Lung Cancer

What the New NCCN Guidelines Mean for RET+ Lung Cancer

The recent NCCN Guideline update represents an important advancement in the treatment of early-stage NSCLC.
June 19, 2026
ASCO 2026 RET Highlights
RET Highlights Presented at the 2026 American Society of Clinical Oncology (ASCO)

RET Highlights Presented at the 2026 American Society of Clinical Oncology (ASCO)

The ASCO Annual Meeting 2026, held in Chicago, brought together oncology experts, researchers, healthcare professionals,…
June 12, 2026
ASCO 2026 selpercatinib trial
ASCO 2026: Selpercatinib Shows Strong Results in Early-Stage RET+ Lung Cancer

ASCO 2026: Selpercatinib Shows Strong Results in Early-Stage RET+ Lung Cancer

Results support the use of selpercatinib in the early-stage setting and highlight the need for…
June 3, 2026
2026 AACR annual meeting RET cancer findings
New AACR 2026 Findings on TP53 Co-Mutations and RET Fusion Partners in RET+ NSCLC

New AACR 2026 Findings on TP53 Co-Mutations and RET Fusion Partners in RET+ NSCLC

New research from the 2026 AACR Annual Meeting shows that certain co-mutations and fusion partners…
May 27, 2026
asco 2026 annual meeting RET feature presentations
RET Cancer Research Takes Center Stage at ASCO, May 2026

RET Cancer Research Takes Center Stage at ASCO, May 2026

The 2026 ASCO Annual Meeting 2026, taking place May 29–June 2 in Chicago, will feature…
May 15, 2026
Don’t Miss Together Separately, presented by LCRF and the Susan Wojcicki Foundation on May 14th, 2026

Don’t Miss Together Separately, presented by LCRF and the Susan Wojcicki Foundation on May 14th, 2026

Join the special edition of Together Separately, presented by LCRF and the Susan Wojcicki Foundation…
April 30, 2026
RET cancer vaccine trial
BioNTech’s BNT116 mRNA cancer vaccine trial currently open at MD Anderson and Johns Hopkins

BioNTech’s BNT116 mRNA cancer vaccine trial currently open at MD Anderson and Johns Hopkins

Exciting news for the RET community! BioNTech’s BNT116 mRNA cancer vaccine trial now enables combination…
April 27, 2026
ARROW clinical trial ret lung cancer findings
Pralsetinib (GAVRETO) for RET+ Lung Cancer: Final ARROW Trial Results

Pralsetinib (GAVRETO) for RET+ Lung Cancer: Final ARROW Trial Results

The findings confirm what many in the RET+ community have been hoping to see: durable…
April 24, 2026
Dr Sarah Waliany RET + lung cancer research RETgistry
New Global Findings from the RETgistry: Advancing Care for RET-Altered Cancers

New Global Findings from the RETgistry: Advancing Care for RET-Altered Cancers

The RETgistry study looked at tumor samples from biopsies of RET patients whose cancers stopped…
April 7, 2026
lung cancer community
The Future of RET Therapy for NSCLC (2026 TTLC Meeting)

The Future of RET Therapy for NSCLC (2026 TTLC Meeting)

The IASLC 2026 Targeted Therapies of Lung Cancer (TTLC) Meeting was held on February 18th. The meeting…
March 26, 2026